The Planning Signal - Pharma Supply Chain Brief (August 2026)

If you advise pharmaceutical manufacturers, the next seven weeks contain more supply-chain-relevant policy change than the last two years:

Section 232 Tariffs: The Second Deadline Lands 29 September

The default duty on covered patented pharmaceuticals is 100% ad valorem, with reduced rates for some origins: 15% for the EU, Japan, South Korea and Switzerland among them, per CBP’s implementation guidance^[1]. Companies named in Annex III have been paying since 31 July; everyone else has until 29 September^[2].

Two details catch planners out. Since 31 July, importers of covered goods must report the Chapter 99 classification whether or not duty is currently payable^[1], and there is no in-transit exception^[3]: what matters is the clearance date, not the sail date. Product shipping from Asia in late August lands directly on the deadline.

Generics: A Two-Year Runway, Then a Cliff

Generics and biosimilars are excluded from Section 232 for now^[2]. But under the plan announced in July, imported generics stay at 0% for two years from 1 August 2026, rise to 100% for August 2028–August 2029, and 200% thereafter for companies without US manufacturing commitments^[4]. That is a network-design question your clients should be modelling now, not in 2028.

The EU Critical Medicines Act Rewrites Procurement Logic

Parliament and Council reached provisional agreement on 12 May 2026^[5], with the final text expected in the Official Journal towards the end of the year. The practical shift: contracting authorities move away from lowest-price awards and must apply resilience requirements in critical-medicines tenders^[6], with EU-preference incentives for medicines heavily dependent on third-country suppliers and a “Strategic Projects” designation giving faster funding and permitting for EU manufacturing of critical medicines and APIs.

Contingency-stock mandates in one member state must not degrade supply elsewhere in the Union^[7], which makes multi-market inventory allocation a compliance issue, not just a cost one.

Shortages Are Rising Again and Lasting Longer

Active US shortages hit 227 in Q2 2026, the third consecutive quarterly increase^[8], though still below the 323 peak of Q1 2024. Roughly half of this year’s new shortages involve single-manufacturer products^[9], and contrast agents alone accounted for 10% of new shortages in 2026.

More striking is USP’s finding that the average shortage now runs over five years^[10], up from 4.3 in 2024 and about two in 2019, while discontinuations jumped 60% from 2024 to 2025, concentrated in the lowest-priced products.

Reshoring: Pledges Are Large, Execution Is Slow

Announced US commitments now exceed $480bn across roughly 22 sites and 44,000 jobs^[11], yet upstream equipment suppliers have not seen matching order flow. On the regulatory side, the FDA named seven PreCheck pilot participants on 29 June^[12] (Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin) from more than 80 applicants, shifting facility-readiness work upstream of the application^[13]. The gap between announcement and validated capacity is where your clients’ 2027–2029 supply plans will be won or lost.

What This Means for the Engagements You’re Running

• Landed cost is now a planning variable, not a finance output. Sourcing decisions, safety-stock placement and pre-deadline build-ahead all move with tariff status by company, origin and HTSUS line. Static annual plans can’t hold this.
• Dual-sourcing arguments finally clear the business case. With half of new shortages sole-source and shortages averaging five years, the cost of a single-site failure now visibly exceeds the cost of qualifying a second source.
• EU and US requirements are pulling in different directions. Clients selling into both need scenario capability at multi-market, multi-echelon level: EU-preference procurement and contingency stocks on one side, tariff-driven US onshoring on the other.

Most of the pharma planning teams we meet are trying to answer these questions in spreadsheets, where a single scenario takes days to build and can’t respect batch sizes, market-specific expiry dates or GMP constraints. That’s a hard place to advise from.

Are You a Supply Chain Consultancy With Pharma Clients?

PLAIO is planning software purpose-built for pharmaceutical supply chains: demand, supply, manufacturing and purchase planning in one system, respecting batch/lot sizes, capacity, lead times and market-based expiry dates, and integrating with SAP and MS Dynamics rather than replacing them. We work alongside consultancies delivering S&OP transformation, network redesign and resilience programmes, and we’re happy to run a joint scenario workshop with a client of yours.

If you have pharma clients facing any of the above, contact us and we’ll set up a 30-minute working session, no deck required. Or see how PLAIO’s supply planning ties tariff status, dual-sourcing and multi-market allocation into a single plan.